BRPI0507875B8 - pró-fármaco de cascata polimérico - Google Patents

pró-fármaco de cascata polimérico

Info

Publication number
BRPI0507875B8
BRPI0507875B8 BRPI0507875A BRPI0507875A BRPI0507875B8 BR PI0507875 B8 BRPI0507875 B8 BR PI0507875B8 BR PI0507875 A BRPI0507875 A BR PI0507875A BR PI0507875 A BRPI0507875 A BR PI0507875A BR PI0507875 B8 BRPI0507875 B8 BR PI0507875B8
Authority
BR
Brazil
Prior art keywords
prodrug
cascade prodrug
polymeric cascade
vehicle
polymeric
Prior art date
Application number
BRPI0507875A
Other languages
English (en)
Inventor
Vetter Dirk
Rau Harald
Schnepf Robert
Wegge Thomas
Hersel Ulrich
Original Assignee
Complex Biosystems Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04075892A external-priority patent/EP1579873A1/en
Priority claimed from GB0415043A external-priority patent/GB0415043D0/en
Priority claimed from EP04019293A external-priority patent/EP1625855A1/en
Application filed by Complex Biosystems Gmbh filed Critical Complex Biosystems Gmbh
Priority to BR122019000248A priority Critical patent/BR122019000248B8/pt
Publication of BRPI0507875A publication Critical patent/BRPI0507875A/pt
Publication of BRPI0507875B1 publication Critical patent/BRPI0507875B1/pt
Publication of BRPI0507875B8 publication Critical patent/BRPI0507875B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ligador de pró-fármaco. pró-fármaco ligado ao veículo de cascata é descrito o qual compreende um componente biologicamente ativo e - um grupo de mascaramento tendo pelo menos um nucleófilo e sendo distinto do veículo. em uma modalidade preferida da invenção, o pró-fármaco possui a estrutura que segue.
BRPI0507875A 2004-03-23 2005-03-22 pró-fármaco de cascata polimérico BRPI0507875B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019000248A BR122019000248B8 (pt) 2004-03-23 2005-03-22 reagente de ligador de pró-fármaco de cascata polimérico

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP04075892.2 2004-03-23
EP04075892A EP1579873A1 (en) 2004-03-23 2004-03-23 Polymeric prodrugs
GB0415043A GB0415043D0 (en) 2004-07-05 2004-07-05 Prodrug linker
GB0415043.9 2004-07-05
EP04019293A EP1625855A1 (en) 2004-08-13 2004-08-13 Polymeric prodrug with a self-immolative linker
EP04019293.2 2004-08-13
PCT/EP2005/003061 WO2005099768A2 (en) 2004-03-23 2005-03-22 Polymeric prodrug with a self-immolative linker

Publications (3)

Publication Number Publication Date
BRPI0507875A BRPI0507875A (pt) 2007-07-24
BRPI0507875B1 BRPI0507875B1 (pt) 2020-11-03
BRPI0507875B8 true BRPI0507875B8 (pt) 2021-05-25

Family

ID=34961964

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019000248A BR122019000248B8 (pt) 2004-03-23 2005-03-22 reagente de ligador de pró-fármaco de cascata polimérico
BRPI0507875A BRPI0507875B8 (pt) 2004-03-23 2005-03-22 pró-fármaco de cascata polimérico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019000248A BR122019000248B8 (pt) 2004-03-23 2005-03-22 reagente de ligador de pró-fármaco de cascata polimérico

Country Status (11)

Country Link
US (4) US8377917B2 (pt)
EP (2) EP1732607B1 (pt)
JP (2) JP4950022B2 (pt)
AU (2) AU2005232371B2 (pt)
BR (2) BR122019000248B8 (pt)
CA (4) CA2786794C (pt)
DK (1) DK1732607T3 (pt)
ES (1) ES2741524T3 (pt)
HU (1) HUE045882T2 (pt)
MX (1) MXPA06010782A (pt)
WO (1) WO2005099768A2 (pt)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EA006484B1 (ru) 2001-02-02 2005-12-29 Конджачем, Инк. Долгоживущие производные рилизинг-фактора гормона роста
DK1732607T3 (da) * 2004-03-23 2019-07-22 Ascendis Pharma Gmbh Polymer-prodrug med en selvofrende linker
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
WO2007083984A1 (en) * 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
EP2114437A2 (en) 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
CA2686068A1 (en) 2007-05-14 2008-11-20 Tyco Healthcare Group Lp Biodegradable peptide releasing polymers
US9353170B2 (en) 2007-06-08 2016-05-31 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
JP2010533202A (ja) * 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
JP5798320B2 (ja) 2007-09-24 2015-10-21 ノクソン・ファルマ・アクチエンゲゼルシャフト Ｃ５ａに結合する核酸
US8263704B2 (en) 2008-04-23 2012-09-11 Tyco Healthcare Group Lp Bioabsorbable surgical composition
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
SI2279007T1 (sl) * 2008-04-29 2016-09-30 Ascendis Pharma Growth Disorders Division A/S Spojine pegiliranega rekombinantnega humanega rastnega hormona
WO2009156481A1 (en) * 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
DK2306986T3 (en) 2008-06-26 2018-06-18 Prolynx Llc PRODRUGS AND PHARMACEUTICAL Macromolecule Conjugates with Controlled Drug Release Rates
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
AU2010220324A1 (en) 2009-03-05 2011-09-01 Ascendis Pharma As Interferon alpha carrier prodrugs
WO2010108657A2 (en) 2009-03-23 2010-09-30 Noxxon Pharma Ag C5a binding nucleic acids and the use thereof
DK3175863T3 (da) 2009-05-20 2022-02-07 Biomarin Pharm Inc Varianter af c-type natriuretisk peptid
EP2459228B1 (en) 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an insulin linker conjugate
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
KR101759499B1 (ko) * 2009-07-31 2017-07-19 사노피-아벤티스 도이칠란트 게엠베하 지속형 인슐린 조성물
CA2769162C (en) * 2009-07-31 2017-12-05 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
CN102781231B (zh) * 2009-10-26 2014-12-24 德瑞迪克纳米科技公司 用于农业中的peham树枝状化合物
WO2011051406A1 (en) 2009-10-29 2011-05-05 Ascendis Pharma As Sterilization of biodegradable hydrogels
HUE038405T2 (hu) 2009-12-15 2018-10-29 Ascendis Pharma Endocrinology Div A/S Átmenetileg polimer hordozóhoz kapcsolt száraz növekedési hormon készítmény
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
EP2525830B1 (en) 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
JP2013528665A (ja) 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
KR20180130008A (ko) 2010-04-15 2018-12-05 올리가시스 고분자량 쌍성이온-함유 중합체
EP2561079A1 (en) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids
WO2012025251A1 (en) 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
ES2678497T3 (es) 2010-09-09 2018-08-13 Noxxon Pharma Ag Ácidos nucleicos que se unen a SDF-1 y su uso en el tratamiento del cáncer
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
EP2633053A1 (en) 2010-10-29 2013-09-04 Noxxon Pharma AG Use of hepcidin binding nucleic acids for depletion of hepcidin from the body
CA2824073A1 (en) 2011-01-10 2012-07-19 Noxxon Pharma Ag Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
WO2013024048A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
AU2012296949B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
AU2012296955B2 (en) 2011-08-12 2016-12-15 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
MX2014003993A (es) 2011-10-12 2014-08-08 Ascendis Pharma Ophthalmology Division As Prevencion y tratamiento de condiciones oculares.
SG11201401362TA (en) 2011-10-21 2014-05-29 Noxxon Pharma Ag Glucagon binding nucleic acids
AU2012331279A1 (en) 2011-11-03 2014-05-08 Bayer Intellectual Property Gmbh Tyrosine based linkers for the releasable connection of peptides
JOP20190001B1 (ar) 2011-11-03 2022-03-14 Bayer Pharma AG عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
EP2802659A1 (en) 2012-01-10 2014-11-19 Noxxon Pharma AG Nucleic acids specifically binding cgrp
EP2802660B1 (en) 2012-01-10 2020-02-19 APTARION biotech AG New c5a binding nucleic acids
JP6522496B2 (ja) 2012-05-16 2019-05-29 ノクソン ファーマ エージー Ｌ−核酸の酵素性合成
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc CHIMERIC COAGULATION FACTORS
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
SG11201501914XA (en) 2012-10-11 2015-05-28 Ascendis Pharma Ophthalmology Division As Vegf neutralizing prodrugs for the treatment of ocular conditions
RU2647729C2 (ru) 2012-10-11 2018-03-19 Асцендис Фарма Ас Пролекарства на основе гидрогеля
AU2013328774B2 (en) 2012-10-11 2017-11-30 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
CN102924725B (zh) * 2012-11-29 2014-11-26 中国科学院长春应用化学研究所 一种聚氨基酸/壳聚糖复合材料及其制备方法
RU2015129800A (ru) * 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
EP2786766A1 (en) * 2013-04-05 2014-10-08 Ufpeptides S.r.l. Supramolecular aggregates comprising maleimido cores
CA2907830C (en) 2013-04-22 2022-03-29 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
EP3054981B1 (en) * 2013-10-08 2020-07-29 Ascendis Pharma A/S Protecting group comprising a purification tag
KR20240034882A (ko) 2013-10-15 2024-03-14 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
WO2015062743A1 (en) 2013-11-04 2015-05-07 Noxxon Pharma Ag Means and methods for the treatment of nephropathy
CA2929201A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
KR20240010081A (ko) * 2013-12-19 2024-01-23 씨젠 인크. 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
US20170073465A1 (en) * 2014-02-28 2017-03-16 Michigan Molecular Institute Sustained release composition using biobased biodegradable hyperbranched polyesters
ES2779974T3 (es) 2014-06-13 2020-08-21 Tenboron Oy Conjugados que comprenden un anticuerpo anti-egfr1
KR20170020868A (ko) 2014-06-20 2017-02-24 바이오얼라이언스 씨.브이. 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법
WO2016020373A1 (en) 2014-08-06 2016-02-11 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
JP2018500272A (ja) 2014-09-26 2018-01-11 バイエル ファーマ アクチエンゲゼルシャフト 安定化アドレノメデュリン誘導体およびその使用
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
DK3653227T5 (da) * 2014-11-18 2023-08-21 Ascendis Pharma Endocrinology Div A/S Hidtil ukendte polymere hgh-prodrugs
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
EP3303365A4 (en) 2015-05-29 2019-04-24 Ascendis Pharma Inc. PRODRUGS WITH A PYROGLUTAMATE LINKER
AU2016316846B2 (en) * 2015-08-28 2021-07-08 Ventana Medical Systems, Inc. Protein proximity assay in formalin fixed paffafin embedded tissue using caged haptens
KR102373744B1 (ko) 2016-01-08 2022-03-15 아센디스 파마 그로우쓰 디스오더스 에이/에스 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
BR112018011152A2 (pt) 2016-01-08 2018-11-21 Ascendis Pharma Growth Disorders As agonistas de cnp de liberação controlada com estabilidade em nep aumentada
IL259658B1 (en) 2016-01-08 2024-02-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with reduced side effects
AU2017205268B2 (en) 2016-01-08 2022-02-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
LT3400019T (lt) 2016-01-08 2022-12-12 Ascendis Pharma Growth Disorders A/S Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
IL301616A (en) * 2016-03-01 2023-05-01 Ascendis Pharma Bone Diseases As PTH medications
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINE LINKS AND INTERMEDIATES THEREOF
US11371045B2 (en) 2016-04-15 2022-06-28 Noxxon Pharma Ag Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
AU2017295938C1 (en) 2016-07-13 2021-10-07 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
DK3518961T3 (da) 2016-09-29 2023-04-24 Ascendis Pharma Bone Diseases As PTH-forbindelser med lave forhold mellem top og bund
PL3518960T3 (pl) 2016-09-29 2023-12-27 Ascendis Pharma Bone Diseases A/S Schemat dawkowania związku pth o kontrolowanym uwalnianiu
US11564974B2 (en) 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
US20190224329A1 (en) 2016-09-29 2019-07-25 Ascendis Pharma Bone Diseases A/S Incremental Dose Finding in Controlled-Release PTH Compounds
JP7152408B2 (ja) 2017-03-10 2022-10-12 キアペグ ファーマシューティカルズ アクチエボラグ 遊離可能コンジュゲート
SG10202107829YA (en) 2017-03-22 2021-08-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
IL308797A (en) * 2018-03-28 2024-01-01 Ascendis Pharma Oncology Div A/S IL-2 conjugates
BR112020022306A2 (pt) 2018-05-18 2021-02-23 Ascendis Pharma Bone Diseases A/S dose de partida de conjugados de pth
BR112021004689A2 (pt) 2018-09-12 2021-06-08 Quiapeg Pharmaceuticals Ab conjugados glp-1 liberáveis
CA3114329A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Novel hydrogel conjugates
AU2019350376A1 (en) 2018-09-26 2021-03-18 Ascendis Pharma A/S Treatment of infections
CA3114272A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
US20220062428A1 (en) * 2018-12-12 2022-03-03 The General Hospital Corporation Prodrugs with a tridentate self-immolative linker
WO2020141225A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Minimization of systemic inflammation
CA3125533A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Conjugates of pattern recognition receptor agonists
KR20210113272A (ko) 2019-01-04 2021-09-15 아센디스 파마 온콜로지 디비전 에이/에스 선천 면역 작용제를 위한 지속되는 국소 약물 수준
EP3906018A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
JP2022520193A (ja) 2019-02-11 2022-03-29 アセンディス ファーマ グロース ディスオーダーズ エー／エス Ｃｎｐコンジュゲートの乾燥医薬製剤
EP3923905A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
CA3131817A1 (en) 2019-03-04 2020-09-10 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
JP2022537369A (ja) 2019-06-18 2022-08-25 バイエル アクチェンゲゼルシャフト 長期安定化のためのアドレノメデュリン－類似体およびその使用
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
EP3986471A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
TW202114660A (zh) 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 酪胺酸激酶抑制劑結合物
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254606A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
US20220305136A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
CA3143436A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of .pi.-electron-pair-donating heteroaromatic nitrogen-comprising compounds
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4084872A1 (en) 2020-01-03 2022-11-09 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
US20230042670A1 (en) 2020-01-13 2023-02-09 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism Treatment
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
AU2021319863A1 (en) 2020-08-05 2023-02-16 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
AU2021349316A1 (en) 2020-09-28 2023-04-27 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
KR20230141754A (ko) 2020-10-30 2023-10-10 아박타 라이프 사이언시스 리미티드 Fap-활성화 혈청 반감기 연장된 치료 접합체
CN116981479A (zh) 2020-12-17 2023-10-31 塔夫茨大学信托人 Fap激活的放射治疗诊断法以及与之相关的用途
KR20230164709A (ko) 2021-04-01 2023-12-04 아센디스 파마 에이에스 염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
AU2022350937A1 (en) 2021-09-22 2024-03-21 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023110727A2 (en) 2021-12-13 2023-06-22 Ascendis Pharma Oncology Division A/S Novel cancer treatments with tlr7/8 agonists
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
WO2023247651A1 (en) 2022-06-21 2023-12-28 TME Pharma AG Methods for treating a tumor in a subject
EP4306640A1 (en) 2022-06-21 2024-01-17 TME Pharma AG Method for treating a tumor in a subject
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
WO1999030727A1 (en) * 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2003026577A2 (en) * 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
EP1437143A4 (en) * 2001-09-28 2007-05-09 Santen Pharmaceutical Co Ltd INJECTIONS FOR EYE TISSUE WITH POLYETHYLENE GLYCOL-BOUNDED MEDICINAL PRODUCT
US20040038892A1 (en) * 2001-11-20 2004-02-26 Rory Finn Chemically-modified human growth hormone conjugates
WO2003057716A2 (en) 2002-01-08 2003-07-17 New River Pharmaceuticals, Inc. Dendritic encapsulation of active agents
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
WO2005082023A2 (en) * 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
DK1732607T3 (da) * 2004-03-23 2019-07-22 Ascendis Pharma Gmbh Polymer-prodrug med en selvofrende linker
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
SI2279007T1 (sl) * 2008-04-29 2016-09-30 Ascendis Pharma Growth Disorders Division A/S Spojine pegiliranega rekombinantnega humanega rastnega hormona
EP2459228B1 (en) * 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an insulin linker conjugate
KR101759499B1 (ko) * 2009-07-31 2017-07-19 사노피-아벤티스 도이칠란트 게엠베하 지속형 인슐린 조성물
US9173953B2 (en) * 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
EP2525830B1 (en) * 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2438930A1 (en) * 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Also Published As

Publication number Publication date
WO2005099768A3 (en) 2006-08-10
AU2005232371A1 (en) 2005-10-27
US20210283264A1 (en) 2021-09-16
US9238686B2 (en) 2016-01-19
BR122019000248B8 (pt) 2021-07-27
US20160089448A1 (en) 2016-03-31
EP2087910A2 (en) 2009-08-12
AU2005232371B2 (en) 2010-10-14
JP2012072142A (ja) 2012-04-12
WO2005099768A2 (en) 2005-10-27
EP2087910A3 (en) 2013-05-15
BRPI0507875B1 (pt) 2020-11-03
ES2741524T3 (es) 2020-02-11
BR122019000248B1 (pt) 2020-04-22
AU2010212335A1 (en) 2010-09-09
CA2824093C (en) 2016-10-25
HUE045882T2 (hu) 2020-01-28
JP5436509B2 (ja) 2014-03-05
AU2010212335B2 (en) 2011-06-23
EP2087910B1 (en) 2022-05-04
CA2786794C (en) 2017-09-12
US20130150281A1 (en) 2013-06-13
CA2824093A1 (en) 2005-10-27
CA2786794A1 (en) 2005-10-27
US8377917B2 (en) 2013-02-19
BRPI0507875A (pt) 2007-07-24
CA2602705C (en) 2016-10-25
CA2602705A1 (en) 2005-10-27
JP2007530485A (ja) 2007-11-01
DK1732607T3 (da) 2019-07-22
CA2940803A1 (en) 2005-10-27
US20080241102A1 (en) 2008-10-02
EP1732607B1 (en) 2019-05-15
EP1732607A2 (en) 2006-12-20
MXPA06010782A (es) 2007-03-28
JP4950022B2 (ja) 2012-06-13

Similar Documents

Publication Publication Date Title
BRPI0507875B8 (pt) pró-fármaco de cascata polimérico
ATE550037T1 (de) Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen
BRPI0606145B8 (pt) formas farmacêuticas sólidas de cloridrato de oxicodona resistentes ao rompimento com liberação sustentada
BRPI0607009A2 (pt) stent endoureteral absorvìvel composto reforçada com fibra
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
CL2011000389A1 (es) Composicion adhesiva que comprende un componente de proteina, un polimero funcionalizado de azetidinio y uno o mas componentes que modifican la viscosidad del grupo que consiste de agentes de reduccion de sulfito y/o tioles , donde el ph de la composición se ajusta entre 5,0 y 7,5.
BR0307516A (pt) Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida
AR056395A1 (es) Composicion que comprende asfalto, copolimero de etileno y azufre
BRPI0516620A (pt) composições com ativo amaciante de tecidos concentrado
UY27346A1 (es) Composiciones farmaccuticas que contienen conjuntos de polemero y frrmaco.
BRPI0501449A (pt) Mistura funcional, processos para curar e para curar parcialmente uma mistura funcional, e, adesivo
BRPI0605276A (pt) cordonel de aço para reforço de pneus para uso fora-de-estrada
BRPI0410503B8 (pt) composição tópica e uso da composição
BRPI0508758A (pt) processo para a preparação de cloridrato de oxicodona tendo menos que 25 ppm de 14 - hidroxicodeinona
BRPI0520071A2 (pt) fixação de stent
BRPI0721503A8 (pt) composições e métodos para tratamento de um poço bloqueado por água
BR0109317A (pt) Composições contendo componentes agonistas alfa-2-adrenérgicos
BR0110425B1 (pt) mistura de combustÍvel diesel, e, mÉtodo de produÇço de um combustÍvel com baixo teor de enxofre.
BRPI0402729A (pt) Composições de revestimento contendo solventes
SV2002000343A (es) Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb
BRPI0518081A (pt) fibra elástica e método para melhorar o coeficiente dinámico de fricção de fibras elásticas
BRPI0517990A (pt) composto de carbodiimida ou mistura de compostos de carbodiimida, composição, e, método de tratamento
AR059445A1 (es) Composiciones de antimicoticos ramnolipidicos y metodos de uso relacionados
DE60113511D1 (de) Mischung enthaltend einen inhibitor oder suppressor eines gens und ein molekül,dass an ein expressionprodukt dieses gens bindet
BR0116332A (pt) Processo para o aumento da estabilidade

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. A CLASSIFICACAO IPC ANTERIOR ERA A61K 47/48.

Ipc: A61K 47/58 (2017.01), A61K 47/60 (2017.01), A61K 4

Ipc: A61K 47/58 (2017.01), A61K 47/60 (2017.01), A61K 4

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF